Part three of the trial will involve patients at higher risk of cardiovascular disease due to obesity and elevated CRP levels.

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key ...

A house that sold for $780,000 tops the list of the most expensive residential real estate sales in Guerneville in the past ...

Italy’s lakeside towns like Bellagio, Como and Varenna are famously beautiful, but have become filled with visitors when the ...

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotech company with a market capitalization of $365 million and showing strong momentum with a 13% gain last week, has dosed the ...

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of ...

With up to 4,000 people a day lining up to visit Instagrammable beauty spots in the Dolomites, landowners are taking measures ...

Read about Monte Rosa Therapeutics Inc (GLUE:XNAS) stock and today's latest news and financial updates.

The authentic Walser village, transformed into a scattered hotel, offers immersive experiences in nature, a spa overlooking ...

According to TipRanks.com, Shi is a 3-star analyst with an average return of 1.6% and a 42.3% success rate. Shi covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Co, ...